Predictive Biomarkers and Personalized Medicine Evaluation of Circulating Tumor Cells and Circulating Tumor DNA inNon – SmallCell LungCancer : AssociationwithClinical Endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib